Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ficerafusp alfa - Bicara Therapeutics

Next Previous
Drug Profile

Ficerafusp alfa - Bicara Therapeutics

Alternative Names: BCA-101; EGFR/TGFβ fusion monoclonal antibody - Bicara Therapeutics

Latest Information Update: 11 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bicara Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor inhibitors; T lymphocyte stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Sep 2026 Phase-II clinical trials in Squamous cell cancer (Recurrent, Metastatic disease, Combination therapy, First-line therapy) in USA (Parenteral) (NCT07807163)
  • 02 Jun 2026 Efficacy data from a phase I/Ib trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 02 Jun 2026 Updated Efficacy data from a phase I/Ib trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top